Brown Advisory Inc. lessened its holdings in Iqvia Holdings Inc (NYSE:IQV) by 6.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,513 shares of the medical research company’s stock after selling 750 shares during the period. Brown Advisory Inc.’s holdings in Iqvia were worth $1,337,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Private Advisor Group LLC increased its stake in Iqvia by 51.3% during the third quarter. Private Advisor Group LLC now owns 5,002 shares of the medical research company’s stock valued at $649,000 after acquiring an additional 1,696 shares during the period. Bessemer Group Inc. increased its stake in Iqvia by 7,985.7% during the third quarter. Bessemer Group Inc. now owns 1,698 shares of the medical research company’s stock valued at $220,000 after acquiring an additional 1,677 shares during the period. Prudential Financial Inc. increased its stake in Iqvia by 4.3% during the third quarter. Prudential Financial Inc. now owns 174,861 shares of the medical research company’s stock valued at $22,686,000 after acquiring an additional 7,230 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its stake in Iqvia by 177.2% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,156 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 739 shares during the period. Finally, Artemis Investment Management LLP bought a new position in Iqvia during the third quarter valued at about $12,387,000. Institutional investors own 87.60% of the company’s stock.
A number of research firms have weighed in on IQV. Goldman Sachs Group raised Iqvia from a “buy” rating to a “conviction-buy” rating in a report on Friday, January 11th. Jefferies Financial Group raised Iqvia from a “hold” rating to a “buy” rating and lifted their price objective for the company from $136.00 to $150.00 in a report on Friday, January 18th. Wells Fargo & Co lifted their price objective on Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, February 19th. UBS Group set a $170.00 price objective on Iqvia and gave the company a “buy” rating in a report on Friday, February 15th. Finally, Argus lifted their price objective on Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a report on Monday, February 25th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Iqvia currently has an average rating of “Buy” and an average price target of $146.88.
Iqvia (NYSE:IQV) last announced its earnings results on Thursday, February 14th. The medical research company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.47 by $0.03. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. Iqvia’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 EPS. On average, sell-side analysts predict that Iqvia Holdings Inc will post 5.87 EPS for the current year.
In other news, Director Ronald A. Rittenmeyer sold 3,840 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider W Richard Staub sold 27,025 shares of the business’s stock in a transaction that occurred on Wednesday, February 20th. The stock was sold at an average price of $140.54, for a total value of $3,798,093.50. The disclosure for this sale can be found here. Insiders sold a total of 4,075,345 shares of company stock worth $573,760,078 over the last three months. 6.00% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Brown Advisory Inc. Trims Position in Iqvia Holdings Inc (IQV)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/4239811/brown-advisory-inc-trims-position-in-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Article: What are the FAANG Stocks?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.